Comparative Pharmacology
Head-to-head clinical analysis: AFAXIN versus TRETINOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFAXIN versus TRETINOIN.
AFAXIN vs TRETINOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the sodium-dependent serotonin reuptake transporter (SERT), increasing serotonin levels in the synaptic cleft.
Retinoic acid receptor agonist; binds to RAR and RXR nuclear receptors, modulating gene transcription involved in cell differentiation, proliferation, and apoptosis.
500 mg orally twice daily
Acute promyelocytic leukemia (APL): 45 mg/m2/day orally divided twice daily, as induction therapy.
MODERATE Risk
MODERATE Risk
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged in renal impairment (up to 30 hours).
Clinical Note
moderateTretinoin + Digoxin
"Tretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlitretinoin + Digoxin
"Alitretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTretinoin + Digitoxin
"Tretinoin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlitretinoin + Digitoxin
"Alitretinoin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 0.5-2 hours for the parent drug, but may be prolonged to 10-12 hours after multiple dosing due to reduced clearance; clinical context: t1/2 is short, requiring frequent or continuous dosing to maintain therapeutic levels.
Renal excretion accounts for approximately 60-70% of the administered dose as unchanged drug; biliary/fecal elimination accounts for 20-25% with the remainder as metabolites.
Primarily fecal (approx. 60%) via biliary excretion as metabolites; renal excretion accounts for <15% of a dose as unchanged drug and metabolites.
Category C
Category D/X
Retinoid
Retinoid